Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study Evaluating the Safety and Efficacy of Adding a Single Prophylactic Donor Lymphocyte Infusion (DLI) of Natural Killer Cells Early After Nonmyeloablative, HLA-Haploidentical Hematopoietic Cell Transplantation - A Multi Center Trial

NCT00789776 is registered in ClinicalTrials.gov with Fred Hutchinson Cancer Center as lead sponsor.

NCT NCT00789776
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00789776 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study Evaluating the Safety and Efficacy of Adding a Single Prophylactic Donor Lymphocyte Infusion (DLI) of Natural Killer Cells Early After Nonmyeloablative, HLA-Haploidentical Hematopoietic Cell Transplantation - A Multi Center Trial
Lead sponsor
Fred Hutchinson Cancer Center
Phase
Phase 1/2
Overall status
Completed
Start date
October 13, 2008
Completion date
May 31, 2017
Enrollment
41 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukemia, acute myeloid leukemia, aggressive non-hodgkin lymphoma, diffuse large b-cell lymphoma, previously treated myelodysplastic syndrome, recurrent chronic lymphocytic leukemia, recurrent chronic myelogenous leukemia, bcr-abl1 positive, recurrent indolent adult non-hodgkin lymphoma, recurrent mantle cell lymphoma, recurrent plasma cell myeloma, recurrent small lymphocytic lymphoma, refractory chronic lymphocytic leukemia, refractory hodgkin lymphoma, refractory plasma cell myeloma, refractory small lymphocytic lymphoma, waldenstrom macroglobulinemia